All that you should know about the Company before applying for the IPO.
The public issue of equity shares of Supriya Lifescience Limited will open for subscription on December 16, 2021 and closes on December 20, 2021. It is expected to list on the stock exchanges on December 28, 2021. What does the company do? Why is the company going public? Who are its key competitors? Its key strengths, and lot more. Here’s everything that you want to know about the company to analyse the IPO.
Incorporated in 2008, the Company is one of the key Indian manufacturers and suppliers of Active Pharmaceuticals Ingredients (APIs), with a focus on research and development. It has niche product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic. It is the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-50% and 60-65%, respectively, of the API exports from India, between Fiscal 2017 and 2021. It is among the largest exporters of Salbutamol Sulphate in India contributing to 31% of the API exports from India in FY 2021 in volume terms. The Company has a team of 23 scientists. Its products are registered with various international regulatory authorities such as USFDA, EDQM, NMPA, KFDA, PMDA, TGA, and Taiwan FDA.
Company’s export sales accounted for ~77% of its revenue from operations (in Fiscal 2021). The Company exports its products to 86 countries in key markets like Europe, North America, Latin America, and Asia. The list includes USA, China, Japan, Germany, Spain, Indonesia, South Korea, Switzerland, Brazil, Mexico, Chile, Taiwan, Malaysia, Bangladesh, South Africa, Kenya, Jordan, and Egypt.
It has a modern manufacturing facility located in Parshuram Lote, Maharashtra. Company’s customers include global pharma companies such as Syntec Do Brasil LTDA, American International Chemical Inc, AT Planejamento E Desenbolvimento De Negocios Ltda, Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd, and Mankind Pharma Ltd.
Satish Waman Wagh
Given below are the objectives of the Company –
The Company proposes to utilise the Net Proceeds from the Fresh Issue towards funding the following objects:
The Offer comprises a Fresh Issue by the company and an Offer for Sale by the selling shareholders. The company will not receive any proceeds from the Offer for Sale.
|IPO Size||₹ 700 Crore|
|Offer Mix||Fresh Issue ₹ 200 Crore + Offer For Sale ₹ 500 Crore|
|Price Band||₹ 265 - ₹ 274|
|Lot Size||54 Shares (& in multiples thereof)|
|Face Value||₹ 2|
|Application Amount||Min. ₹ 14,796 (1 lot) | Max. ₹ 1,92,348 (13 lots) [at upper price band]|
|Listing on||NSE & BSE|
|Registrar||Link Intime India Private Limited|
|Cut-off time for UPI Mandate Confirmation||21-Dec-2021 (up to 12:00 PM)|
₹ 525 Crore
(75% of Issue Size)
₹ 105 Crore
(15% of Issue Size)
₹ 70 Crore
(10% of Issue Size)
|IPO Opens||December 16, 2021|
|IPO Closes||December 20, 2021|
|Finalization of the basis of allotment||December 23, 2021|
|Unblocking of funds / Initiation of refunds||December 24, 2021|
|Credit of equity shares to Demat accounts||December 27, 2021|
|Listing of equity shares||December 28, 2021|
Apply online in just 5 minutes!Apply Now Investment in securities market is subject to market risks, read all the related documents carefully before investing.